Maze (MAZE)
Develops small-molecule therapies guided by human genetics for kidney and metabolic diseases.
$26.70
At close+0.17 (+0.64%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
| Institutions176 holders · as of Mar 31, 2026 · largest filers plus last quarter's tail | ≈ 92.31% | 51.28M shares | |
| Insiders6 holders · as of Aug 31, 2026 | 2.16% | 1.20M shares | |
| Strategic holders1 holder · as of Feb 13, 2026 | 8.05% | 4.47M shares | |
| Adds to | 102.52% |
55.55M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
This quarter's institutional total failed a plausibility check; shown: the largest filers plus last quarter's remainder.
These groups come from separate filings that can overlap, so they add to 102.52%; nothing is left for Other.
Institutions13F, as of Mar 31, 2026
176 holders · 51.28M shares · 50 new positions · 109 increased · 36 reduced · 27 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| Frazier Life Sciences Management, L.P. | 4.57M | 8.22% | 0 | May 15, 2026 |
| TRV GP Iv, LLC | 4.47M | 8.05% | 0 | May 7, 2026 |
| Arch Venture Management, LLC | 4.12M | 7.42% | 0 | May 15, 2026 |
| Deep Track Capital, LP | 3.48M | 6.26% | −768.9K | May 15, 2026 |
| Janus Henderson Group PLC | 2.86M | 5.15% | −283.7K | May 18, 2026 |
| Paradigm Biocapital Advisors LP | 2.74M | 4.94% | +2.74Mnew | May 15, 2026 |
| BlackRock, Inc. | 2.57M | 4.63% | +283.3K | May 13, 2026 |
| Ah Capital Management, L.L.C. | 1.70M | 3.06% | 0 | May 15, 2026 |
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| ARCH Venture Fund X, L.P. | 9.40% | 4.12M | 13G | May 15, 2025 ↗ |
| Third Rock Ventures IV, L.P. | 9.30% | 4.47M | 13G | Feb 13, 2026 ↗ |
| Deep Track Capital, LP | 9.02% | 3.95M | 13G | Aug 14, 2025 ↗ |
| Frazier Life Sciences Public Fund, L.P. | 9.00% | 4.34M | 13G | Feb 13, 2026 ↗ |
| Paradigm BioCapital Advisors LP | 6.10% | 3.05M | 13G | Apr 1, 2026 ↗ |
| Janus Henderson Group PLC | 5.80% | 2.86M | 13G | May 15, 2026 ↗ |
| BlackRock, Inc. | 5.40% | 2.98M | 13G | Jul 29, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 28, 2026 | Atul Dandekarofficer: CSBO | Sale | 7,500 | $27.58 | 26,250 |
| Aug 13, 2026 | Harold Bernsteinofficer: President, R&D & CMO | Sale | 16,142 | $27.61 | 0 |
| Aug 3, 2026 | Jason V. Colomadirector, officer: Chief Executive Officer | Sale · 4 lots | 34,501 | $26.73 | 20,744 |
| Jul 29, 2026 | Atul Dandekarofficer: CSBO | Sale · 2 lots | 7,500 | $27.34 | 26,250 |
| Jul 1, 2026 | Jason V. Colomadirector, officer: Chief Executive Officer | Sale · 3 lots | 34,501 | $29.98 | 23,337 |
| Jul 1, 2026 | Harold Bernsteinofficer: President, R&D & CMO | Sale · 2 lots | 14,609 | $29.90 | 0 |
| Jun 29, 2026 | Atul Dandekarofficer: CSBO | Sale | 7,500 | $28.02 | 26,250 |
| Jun 22, 2026 | Jason V. Colomadirector, officer: Chief Executive Officer | Sale · 2 lots | 3,993 | $26.00 | 25,930 |
| Jun 23, 2026 | Jason V. Colomadirector, officer: Chief Executive Officer | Sale | 23,865 | $26.05 | 319,079 |
| Jun 1, 2026 | Harold Bernsteinofficer: President, R&D & CMO | Sale · 2 lots | 14,853 | $25.66 | 0 |
CongressHouse and Senate disclosures
Not reported.